Greystone Financial Group LLC Has $711,000 Stock Position in Cencora, Inc. (NYSE:COR)

Greystone Financial Group LLC increased its stake in Cencora, Inc. (NYSE:COR) by 2.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,159 shares of the company’s stock after purchasing an additional 64 shares during the period. Greystone Financial Group LLC’s holdings in Cencora were worth $711,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Financial Advocates Investment Management raised its holdings in shares of Cencora by 4.7% during the second quarter. Financial Advocates Investment Management now owns 978 shares of the company’s stock valued at $220,000 after purchasing an additional 44 shares during the period. Checchi Capital Advisers LLC boosted its stake in shares of Cencora by 2.2% in the 2nd quarter. Checchi Capital Advisers LLC now owns 2,217 shares of the company’s stock worth $499,000 after buying an additional 48 shares during the last quarter. Valeo Financial Advisors LLC grew its holdings in shares of Cencora by 3.4% in the second quarter. Valeo Financial Advisors LLC now owns 1,566 shares of the company’s stock valued at $353,000 after acquiring an additional 51 shares in the last quarter. Evergreen Capital Management LLC lifted its holdings in Cencora by 4.7% during the second quarter. Evergreen Capital Management LLC now owns 1,147 shares of the company’s stock worth $258,000 after acquiring an additional 52 shares during the period. Finally, Vontobel Holding Ltd. grew its position in Cencora by 1.4% during the third quarter. Vontobel Holding Ltd. now owns 4,250 shares of the company’s stock valued at $957,000 after buying an additional 58 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Price Performance

Shares of NYSE:COR opened at $234.52 on Thursday. The company has a market capitalization of $46.78 billion, a P/E ratio of 25.66, a P/E/G ratio of 1.40 and a beta of 0.44. Cencora, Inc. has a 1-year low of $182.75 and a 1-year high of $247.66. The firm’s 50 day simple moving average is $232.25 and its two-hundred day simple moving average is $230.88. The company has a debt-to-equity ratio of 3.93, a current ratio of 0.89 and a quick ratio of 0.55.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $3.34 EPS for the quarter, beating analysts’ consensus estimates of $3.18 by $0.16. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The business had revenue of $74.20 billion for the quarter, compared to analysts’ expectations of $73.32 billion. During the same period last year, the firm earned $2.92 earnings per share. The business’s quarterly revenue was up 10.8% on a year-over-year basis. Research analysts expect that Cencora, Inc. will post 13.63 EPS for the current fiscal year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 9th were issued a $0.51 dividend. The ex-dividend date of this dividend was Friday, August 9th. This represents a $2.04 annualized dividend and a dividend yield of 0.87%. Cencora’s dividend payout ratio (DPR) is 22.32%.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Bank of America reaffirmed a “neutral” rating and issued a $245.00 price target (down from $275.00) on shares of Cencora in a report on Wednesday, September 18th. Leerink Partners cut their price target on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a research note on Monday, October 7th. StockNews.com lowered Cencora from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 20th. JPMorgan Chase & Co. upped their price target on shares of Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a research report on Wednesday, August 21st. Finally, Evercore ISI lowered their price objective on Cencora from $270.00 to $250.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $259.44.

Insider Buying and Selling

In related news, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction dated Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total value of $5,071,822.20. Following the completion of the transaction, the chairman now owns 285,088 shares in the company, valued at approximately $67,223,750.40. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction dated Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total value of $5,071,822.20. Following the completion of the transaction, the chairman now owns 285,088 shares in the company, valued at approximately $67,223,750.40. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $240.56, for a total value of $1,067,646,415.76. Following the transaction, the insider now owns 19,980,000 shares of the company’s stock, valued at $4,806,388,800. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 4,461,153 shares of company stock worth $1,073,075,720. Corporate insiders own 15.80% of the company’s stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.